EMBC vs LLY: fair value comparison
Embecta Corp. and Eli Lilly and Company · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our discount ranking. EMBC carries the stronger quality grade.
| EMBC | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $3.72 | $1,149.36 |
| 12-month range | $3.29–$14.27 | $862.86–$1,160.00 |
| Sector rank | #3 of 113 Healthcare | #11 of 113 Healthcare |
| Quality grade | C- | D |
| Momentum grade | B | — |
| Leverage | Low | High |
| Margin trend | — | Expanding |
| Revenue growth | — | High |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: EMBC fair value analysis · LLY fair value analysis